Canada Releases New Safety Information for Tarceva

Filed December 19th, 2008 meg

Hoffmann-La Roche Limited, in consultation with Health Canada, has informed Canadian health care professionals of new important safety information regarding the use of TARCEVA® (erlotinib) in patients with moderate liver impairment and advanced cancer.

TARCEVA is used to treat patients with non-small cell lung cancer at an advanced stage in which chemotherapy has not helped to stop the disease.

A number of patients with liver impairment died during treatment or within 30 days of the last dose compared to patients with normal liver function.

The new safety information suggests that patients currently on or who have recently taken TARCEVA should have their liver function closely monitored by their doctor.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • blinkbits
  • BlinkList
  • blogmarks
  • feedmelinks

    Latest Drug News

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!